Copy
Caladrius Biosciences Third Quarter 2015 Financial Results Conference 
Hi SWI Subscribers.

This is your opportunity to get a detailed update directly from the new management team, since "Neostem" became "Caladrius Biosciences". Please don't miss the opportunity to ask your questions.

Rainer Poertner
Chief Analyst
StockWatchIndex


 

 

Caladrius Biosciences to Host Third Quarter 2015 Financial Results Conference Call on November 5 at 5:00 pm

 
Basking Ridge, N.J., Oct. 29, 2015 -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) (“Caladrius”), a company combining a leading cell therapy service provider with a development pipeline including a Phase 3 clinical program in immuno-oncology and a portfolio of projects in immune modulation and ischemic repair, today announced that the Company will release financial results for the three and nine months ended September 30, 2015, after the market close on Thursday, November 5, 2015.

Caladrius’ management will host a conference call for the investment community beginning at 5:00 pm ET on Thursday, November 5, 2015, to discuss the financial results and to answer questions.

Shareholders and other interested parties may participate in the conference call by dialing (877) 562-4460 (US) or (513) 438-4106 (International) and entering passcode 95709215. The call will also be broadcast live on the Internet via the Company’s website at www.caladrius.com/events.

The call will be archived on the Company’s website for 90 days at www.caladrius.com/events.

About Caladrius Biosciences

Caladrius Biosciences, Inc. is among the first of a new breed of immunotherapy companies with proven expertise and unique experience in cell process optimization, development and manufacturing. Caladrius combines a leading cell therapy service provider with a development pipeline including late-stage clinical programs based on proprietary platform technology for immuno-oncology, as well as additional platform technologies for immunomodulation and ischemic repair. This integrated approach supports the industry in bringing significant life-improving medical treatments to market.  www.caladrius.com    

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy, the Company's ability to develop and grow its business, the successful development of cellular therapies with respect to the Company's research and development and clinical evaluation efforts in connection with the Company's Immuno-oncology Program, Ischemic Repair Program, Immune Modulation Program and other cell therapies, the future of the regenerative medicine industry and the role of stem cells and cellular therapy in that industry, and the performance and planned expansion of the Company's wholly-owned subsidiary and its center of excellence for cell therapy process development, engineering and manufacturing, PCT, as well as its efforts to expand its capabilities into the cell therapy tools market. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission ("SEC") on March 2, 2015, and in the Company's other periodic filings with the SEC. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside of its control.

 
About Caladrius Biosciences, Inc. (formerly NeoStem, Inc.)
Caladrius Biosciences, Inc. is among the first of a new breed of immunotherapy companies with proven expertise and unique experience in cell process optimization, development, and manufacturing. Caladrius is a cell therapy leader with late-stage clinical programs based on a proprietary platform technology for immuno-oncology, as well as additional platform technologies for ischemic repair and immunomodulation, and capabilities that support other cell therapy developers. This integrated approach supports the industry in bringing significant life-improving medical treatments to market.  www.caladrius.com  
 
Contact:
Calidrius/NeoStem, Inc.
Eric Powers
Manager of Communications and Marketing
Phone: +1-212-584-4173
Email: epowers@neostem.com

 
Please visit our research service site www.swiresearch.com. We would appreciate if you could pass our newsletter on to your friends and colleagues and naturally, we always appreciate your feedback and comments.
 
 
 
About SWI
SWI is a leading edge PR, Information Marketing and Research firm with a highly frequented web site www.stockwatchindex.com, its "Rise Above The Noise" newsletter and SWI Research site www.swiresearch.com. These services provide readers with information and research on new, often undiscovered and promising public companies. The QuickPicks section on the SWI site represents the consolidated opinions of carefully selected financial analyst reports and opinions from credible Wall Street firms that we respect and frequently sample. Our weekly SWI QuickPicks  Ratings Report keeps you informed about newly SWI initiated stocks and potential upgrades and downgrades in the QuickPicks section. We are not being compensated by these companies and do not necessarily hold positions in any of these stocks.  You can conveniently follow the live links for each of these stocks on http://www.stockwatchindex.com/swi-quickpicks for more detail.  SWI's  "Portfolio Performance Report" periodically reports about the performance of the stocks that we have purchased in our portfolio. typically hold and may be trading.  Please do not miss the wealth of frequently updated news, research reports and other valuable information elsewhere on SWI, especially for the stocks on our WatchIndex page. Watch a full range of CEO and analyst interviews on our Strategic Partner site www.wideworldofstocks.com.  
 
Facebook
Twitter
LinkedIn
Google +
StockWatchIndex
 
Good luck and please pass this newsletter on to a friend
to continue building our community.
 

StockWatchIndex (SWI) is not a registered investment adviser and makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise) of the information provided in the publications for its Stock Watch List or on its web sites. The provided information is not to be construed as personal financial advice, or a solicitation to buy or sell stock. Some information has been generated by what SWI deems to be reliable third party entities, but SWI does not guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or  warrants any results from use of the information. We have contracted with some of the companies we present on SWI or in the SWI Newsletter as public relations consultants to keep the market and especially our subscribers informed about the companies and may have been compensated in cash and/or stock and stock options, which may be considered a potential conflict of interest. Readers are encouraged to consult their personal financial adviser before making any decisions to buy, sell or hold any securities mentioned herein. StockWatchIndex is not responsible for any error, mistake or shortcoming that may be occasioned at the time of publishing of the information in its Stock Watch List or in any of its other publications. No liability is accepted by StockWatchIndex whatsoever for any direct, indirect or consequential loss arising from the use of the information. StockWatchIndex expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information provided. The included information is subject to change without notice.

Copyright © 2015 StockWatchIndex, LLC, All rights reserved.


unsubscribe from this list    update subscription preferences 

Email Marketing Powered by Mailchimp